Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Unlimited Watchlists, Portfolios, Screeners, and other Barchart tools. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals (REGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 81,861,632
  • Shares Outstanding, K 108,902
  • Annual Sales, $ 16,072 M
  • Annual Income, $ 8,075 M
  • 60-Month Beta 0.20
  • Price/Sales 4.99
  • Price/Cash Flow 9.11
  • Price/Book 3.74
Trade REGN with:

Options Overview Details

View History
  • Implied Volatility 26.93% ( -1.22%)
  • Historical Volatility 23.12%
  • IV Percentile 5%
  • IV Rank 7.39%
  • IV High 41.71% on 09/29/22
  • IV Low 25.75% on 03/29/22
  • Put/Call Vol Ratio 1.07
  • Today's Volume 1,542
  • Volume Avg (30-Day) 2,919
  • Put/Call OI Ratio 1.14
  • Today's Open Interest 47,743
  • Open Int (30-Day) 52,322

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate 8.41
  • Number of Estimates 7
  • High Estimate 11.14
  • Low Estimate 4.23
  • Prior Year 23.72
  • Growth Rate Est. (year over year) -64.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
702.07 +7.07%
on 11/03/22
769.63 -2.33%
on 11/09/22
+0.94 (+0.13%)
since 10/28/22
3-Month
572.22 +31.37%
on 09/06/22
769.63 -2.33%
on 11/09/22
+163.31 (+27.76%)
since 08/30/22
52-Week
538.01 +39.72%
on 06/14/22
769.63 -2.33%
on 11/09/22
+108.35 (+16.84%)
since 11/26/21

Most Recent Stories

More News
Should Goldman Sachs Equal Weight U.S. Large Cap Equity ETF (GSEW) Be on Your Investing Radar?

Style Box ETF report for GSEW

GSEW : 61.55 (+2.79%)
REGN : 751.70 (+2.12%)
SPY : 407.68 (+3.15%)
IVV : 409.32 (+3.10%)
ZS : 133.45 (-1.04%)
COIN : 45.73 (+6.08%)
Evkeeza® (evinacumab-dgnb) sBLA for Children with Ultra-rare Inherited Form of High Cholesterol Accepted for FDA Priority Review

/PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the...

REGN : 751.70 (+2.12%)
2 Market-Beating Stocks That Can Continue Rising in 2023

It's not too late to get in on the potential 2023 growth for these two stocks.

REGN : 751.70 (+2.12%)
TMUS : 151.46 (+1.91%)
Regeneron (REGN) Outperforms YTD: What's in Store for 2023?

Regeneron (REGN) has had a good run in 2022 so far and the momentum should continue in 2023 as well.

REGN : 751.70 (+2.12%)
SNY : 45.35 (-1.13%)
BAYRY : 14.5600 (+0.12%)
Biotech Stock Roundup: CTMX Surges on REGN's Deal, APLS Up on Regulatory Update

Updates from CTMX and APLS are the key highlights from the biotech sector during the past week.

REGN : 751.70 (+2.12%)
CTMX : 1.7400 (+2.35%)
APLS : 49.93 (-0.38%)
INM : 2.65 (+2.32%)
Regeneron's (REGN) Libtayo Gets EC Nod for Cervical Cancer

Regeneron (REGN) gets EC's approval for the label expansion of PD-1 inhibitor Libtayo for the treatment of adult patients with recurrent or metastatic cervical cancer.

REGN : 751.70 (+2.12%)
SNY : 45.35 (-1.13%)
BIIB : 305.17 (+4.72%)
SNDX : 23.96 (+7.83%)
Libtayo® (cemiplimab) Approved by the European Commission as the First Immunotherapy in Second Line Recurrent or Metastatic Cervical Cancer Irrespective of PD-L1 Expression Level or Tumor Histology

/PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Commission (EC) approved Libtayo® (cemiplimab) as monotherapy...

REGN : 751.70 (+2.12%)
CytomX (CTMX) Stock Surges on Oncology Deal With Regeneron

CytomX (CTMX) gets a boost after its deal with Regeneron for the development of investigational next-generation bispecific immunotherapies.

REGN : 751.70 (+2.12%)
AMGN : 286.40 (+1.56%)
ABBV : 161.18 (+1.88%)
CTMX : 1.7400 (+2.35%)
CytomX Therapeutics (NASDAQ: CTMX) and Regeneron (NASDAQ: REGN) Enter into Strategic Collaboration to Develop Bispecific Therapies to Treat Cancer

CytomX Therapeutics, Inc. (NASDAQ: CTMX) is a clinical-stage biopharmaceutical company, which is focused on developing innovative treatments for a wide-range

CTMX : 1.7400 (+2.35%)
REGN : 751.70 (+2.12%)
Bayer (BAYRY) Eylea Label Extension Gets CHMP Positive Opinion

Bayer (BAYRY) gets positive recommendation from the CHMP for label extension of ophthalmology drug Eylea for the treatment of preterm infants with retinopathy of prematurity.

REGN : 751.70 (+2.12%)
BAYRY : 14.5600 (+0.12%)
PBYI : 4.52 (-0.88%)
SNDX : 23.96 (+7.83%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting serious medical conditions. The company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. The company also...

See More

Key Turning Points

3rd Resistance Point 788.57
2nd Resistance Point 772.29
1st Resistance Point 761.99
Last Price 751.70
1st Support Level 735.41
2nd Support Level 719.13
3rd Support Level 708.83

See More

52-Week High 769.63
Last Price 751.70
Fibonacci 61.8% 681.15
Fibonacci 50% 653.82
Fibonacci 38.2% 626.49
52-Week Low 538.01

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar